TY - JOUR
T1 - A diagnostic marker to discriminate childhood apraxia of speech from speech delay
T2 - Ii. validity studies of the pause marker
AU - Shriberg, Lawrence D.
AU - Strand, Edythe A.
AU - Fourakis, Marios
AU - Jakielski, Kathy J.
AU - Hall, Sheryl D.
AU - Karlsson, Heather B.
AU - Mabie, Heather L.
AU - McSweeny, Jane L.
AU - Tilkens, Christie M.
AU - Wilson, David L.
N1 - Funding Information:
This research was supported by National Institute on Deafness and Other Communication Disorders Grant DC000496, awarded to Lawrence D. Shriberg, and by a core grant, National Institute of Child Health and Development Grant HD03352, to the Waisman Center. The sixth and ninth authors made the original and substantial continuing contributions that led to the development of the Pause Marker. We are grateful to the following colleagues and collaborators for their significant contributions to this research: Len Abbeduto, Nancy Alarcon, Becky Baas, Adriane Baylis, Richard Boada, Roger Brown, Stephen Camarata, Thomas Campbell, Richard Folsom, Lisa Freebairn, Jordan Green, Barbara Lewis, Christopher Moore, Katherine Odell, Bruce Pennington, Nancy Potter, Jonathan Preston, Erin Redle, Heather Leavy Rusiewicz, Alison Scheer-Cohen, Kristie Spencer, Ruth Stoeckel, Bruce Tomblin, Jennifer Vannest, and Emily White. We also thank the many participants, parents of participants, and research colleagues who have contributed insights into the needs and issues in diagnostic research in childhood apraxia of speech.
Publisher Copyright:
© 2017 American Speech-Language-Hearing Association.
PY - 2017/4
Y1 - 2017/4
N2 - Purpose: The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method: PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results: Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion: These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
AB - Purpose: The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method: PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results: Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion: These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
UR - http://www.scopus.com/inward/record.url?scp=85017519720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017519720&partnerID=8YFLogxK
U2 - 10.1044/2016_JSLHR-S-15-0297
DO - 10.1044/2016_JSLHR-S-15-0297
M3 - Article
C2 - 28384803
AN - SCOPUS:85017519720
SN - 1092-4388
VL - 60
SP - S1118-S1134
JO - Journal of Speech and Hearing Disorders
JF - Journal of Speech and Hearing Disorders
IS - 4
ER -